Interestingly, our findings suggest that chronic administration of CB2 agonist should most likely be combined with FAAH and/or MAGL inhibitors to prevent the generation of a pool of free fatty acid leading to increase in tumor growth and endocannabinoid (AEA, 2-AG) levels in ovarian cancer. The gene discussed is MGLL; the disease is ovarian carcinoma.